Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04496245
Registration number
NCT04496245
Ethics application status
Date submitted
26/07/2020
Date registered
3/08/2020
Titles & IDs
Public title
Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85
Query!
Scientific title
Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85
Query!
Secondary ID [1]
0
0
BV-2020/19
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
COVIDRASP
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Respiratory Viral Infection
0
0
Query!
Covid19
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Respiratory
0
0
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Broncho-Vaxom®
Active comparator: Wait-list control - One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment.
Experimental: Initial treatment wtih OM85 - One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing on day 0, with 3 months follow-up off treatment.
Treatment: Drugs: Broncho-Vaxom®
Broncho-Vaxom adult capsules® (OM85)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Acute Respiratory Infection necessitating workforce removal
Query!
Assessment method [1]
0
0
The proportion of Health Care Workers contracting an Acute Respiratory Infection necessitating workforce removal in the initial treatment and wait-list control groups assessed at the end of 3 months.
Query!
Timepoint [1]
0
0
3 months
Query!
Secondary outcome [1]
0
0
Time to ARI necessitating workforce removal.
Query!
Assessment method [1]
0
0
The time to the first ARI necessitating workforce removal in the initial treatment and wait-list control groups.
Query!
Timepoint [1]
0
0
12 months
Query!
Secondary outcome [2]
0
0
The proportion of Health Care Workers contracting an Acute Respiratory Infection necessitating workforce removal
Query!
Assessment method [2]
0
0
The proportion of Health Care Workers contracting an Acute Respiratory Infection necessitating workforce removal in the initial treatment and wait-list control groups assessed at the end of 6 and 12 months
Query!
Timepoint [2]
0
0
12 months
Query!
Secondary outcome [3]
0
0
The proportion of HCW with documented Cov infection.
Query!
Assessment method [3]
0
0
The proportion of HCW in the initial treatment and wait-list control group with Cov infection documented by molecular techniques of seroconversion
Query!
Timepoint [3]
0
0
12 months
Query!
Secondary outcome [4]
0
0
Time to Lower respiratory infection (LRI) necessitating workforce removal.
Query!
Assessment method [4]
0
0
The time to the first LRI necessitating workforce removal in the initial treatment and wait-list control groups.
Query!
Timepoint [4]
0
0
12 months
Query!
Secondary outcome [5]
0
0
The proportion of Health Care Workers contracting a LRI necessitating workforce removal
Query!
Assessment method [5]
0
0
The proportion of Health Care Workers contracting LRI necessitating workforce removal in the initial treatment and wait-list control groups assessed at the end of 3, 6 and 12 months
Query!
Timepoint [5]
0
0
12 months
Query!
Secondary outcome [6]
0
0
The proportion of HCW with documented Cov LRI.
Query!
Assessment method [6]
0
0
The proportion of HCW in the initial treatment and wait-list control group with LRI due to Cov infection documented by molecular techniques of seroconversion
Query!
Timepoint [6]
0
0
12 months
Query!
Eligibility
Key inclusion criteria
Participants who meet all of the following criteria are eligible for enrolment:
1. HCW in front line clinical departments assessing or caring for patients with suspected or verified COV infection in one of the recruiting hospitals in Brisbane
2. Participants who, in the opinion of the investigator, are able to comply with the protocol for its duration,
3. Written informed consent signed and dated according to local regulations.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
100
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Participants who meet any of these criteria are not eligible for enrolment:
* Staff with prior COV infection necessitating workforce removal
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
24/08/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
30/09/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
59
Query!
Recruitment in Australia
Recruitment state(s)
QLD
Query!
Recruitment hospital [1]
0
0
The Prince Charles Hospital - Brisbane
Query!
Recruitment hospital [2]
0
0
The Princess Alexandra Hospital - Brisbane
Query!
Recruitment hospital [3]
0
0
Queensland Children's Hospital - South Brisbane
Query!
Recruitment postcode(s) [1]
0
0
4032 - Brisbane
Query!
Recruitment postcode(s) [2]
0
0
4102 - Brisbane
Query!
Recruitment postcode(s) [3]
0
0
4101 - South Brisbane
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
The University of Queensland
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
Griffith University
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Government body
Query!
Name [2]
0
0
The Prince Charles Hospital
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Other collaborator category [3]
0
0
Other
Query!
Name [3]
0
0
Princess Alexandra Hospital, Brisbane, Australia
Query!
Address [3]
0
0
Query!
Country [3]
0
0
Query!
Other collaborator category [4]
0
0
Other
Query!
Name [4]
0
0
Telethon Kids Institute
Query!
Address [4]
0
0
Query!
Country [4]
0
0
Query!
Other collaborator category [5]
0
0
Other
Query!
Name [5]
0
0
Queensland Children's Hospital, South Brisbane, Queensland, Australia
Query!
Address [5]
0
0
Query!
Country [5]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Parallel group, Wait-list design, with treatment delayed for 3 months. Participants will be randomized on a 1:1 ratio with 500 participants per group in Australia. Group 1: Wait-list control. One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing in Month 3, with 3 months follow-up off treatment. Group 2: Initial treatment. One capsule OM85 (7.0 mg) will be given daily for 3 months, commencing on day 0, with 3 months follow-up off treatment.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04496245
Query!
Trial related presentations / publications
Sly PD, Galbraith S, Islam Z, Holt B, Troy N, Holt PG. Primary prevention of severe lower respiratory illnesses in at-risk infants using the immunomodulator OM-85. J Allergy Clin Immunol. 2019 Sep;144(3):870-872.e11. doi: 10.1016/j.jaci.2019.05.032. Epub 2019 Jun 8. No abstract available. Esposito S, Soto-Martinez ME, Feleszko W, Jones MH, Shen KL, Schaad UB. Nonspecific immunomodulators for recurrent respiratory tract infections, wheezing and asthma in children: a systematic review of mechanistic and clinical evidence. Curr Opin Allergy Clin Immunol. 2018 Jun;18(3):198-209. doi: 10.1097/ACI.0000000000000433. The Lancet. COVID-19: protecting health-care workers. Lancet. 2020 Mar 21;395(10228):922. doi: 10.1016/S0140-6736(20)30644-9. No abstract available.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
PETER D SLY, DSc
Query!
Address
0
0
The University of Queensland
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
Study Protocol and Statistical Analysis Plan
https://cdn.clinicaltrials.gov/large-docs/45/NCT04496245/Prot_SAP_001.pdf
Statistical analysis plan
Study Protocol and Statistical Analysis Plan
https://cdn.clinicaltrials.gov/large-docs/45/NCT04496245/Prot_SAP_001.pdf
Informed consent form
https://cdn.clinicaltrials.gov/large-docs/45/NCT04496245/ICF_000.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT04496245